185 related articles for article (PubMed ID: 38492200)
1. Evaluation of the pathogenic potential of germline DDX41 variants in hematopoietic neoplasms using the ACMG/AMP guidelines.
Matsui H; Hirata M
Int J Hematol; 2024 May; 119(5):552-563. PubMed ID: 38492200
[TBL] [Abstract][Full Text] [Related]
2. The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing.
Maierhofer A; Mehta N; Chisholm RA; Hutter S; Baer C; Nadarajah N; Pohlkamp C; Thompson ER; James PA; Kern W; Haferlach C; Meggendorfer M; Haferlach T; Blombery P
Blood Adv; 2023 Dec; 7(23):7346-7357. PubMed ID: 37874914
[TBL] [Abstract][Full Text] [Related]
3. Specifications of the ACMG/AMP Variant Classification Guidelines for Germline
Hatton JN; Frone MN; Cox HC; Crowley SB; Hiraki S; Yokoyama NN; Abul-Husn NS; Amatruda JF; Anderson MJ; Bofill-De Ros X; Carr AG; Chao EC; Chen KS; Gu S; Higgs C; Machado J; Ritter D; Schultz KA; Soper ER; Wu MK; Mester JL; Kim J; Foulkes WD; Witkowski L; Stewart DR
Hum Mutat; 2023; 2023():. PubMed ID: 38084291
[TBL] [Abstract][Full Text] [Related]
4. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.
Li P; Brown S; Williams M; White T; Xie W; Cui W; Peker D; Lei L; Kunder CA; Wang HY; Murray SS; Vagher J; Kovacsovics T; Patel JL
Blood; 2022 Aug; 140(7):716-755. PubMed ID: 35671390
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41.
Homan CC; Drazer MW; Yu K; Lawrence DM; Feng J; Arriola-Martinez L; Pozsgai MJ; McNeely KE; Ha T; Venugopal P; Arts P; King-Smith SL; Cheah J; Armstrong M; Wang P; Bödör C; Cantor AB; Cazzola M; Degelman E; DiNardo CD; Duployez N; Favier R; Fröhling S; Rio-Machin A; Klco JM; Krämer A; Kurokawa M; Lee J; Malcovati L; Morgan NV; Natsoulis G; Owen C; Patel KP; Preudhomme C; Raslova H; Rienhoff H; Ripperger T; Schulte R; Tawana K; Velloso E; Yan B; Kim E; Sood R; Hsu AP; Holland SM; Phillips K; Poplawski NK; Babic M; Wei AH; Forsyth C; Mar Fan H; Lewis ID; Cooney J; Susman R; Fox LC; Blombery P; Singhal D; Hiwase D; Phipson B; Schreiber AW; Hahn CN; Scott HS; Liu P; Godley LA; Brown AL;
Blood Adv; 2023 Oct; 7(20):6092-6107. PubMed ID: 37406166
[TBL] [Abstract][Full Text] [Related]
6. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
Quesada AE; Routbort MJ; DiNardo CD; Bueso-Ramos CE; Kanagal-Shamanna R; Khoury JD; Thakral B; Zuo Z; Yin CC; Loghavi S; Ok CY; Wang SA; Tang Z; Bannon SA; Benton CB; Garcia-Manero G; Kantarjian H; Luthra R; Medeiros LJ; Patel KP
Am J Hematol; 2019 Jul; 94(7):757-766. PubMed ID: 30963592
[TBL] [Abstract][Full Text] [Related]
7. ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.
Luo X; Feurstein S; Mohan S; Porter CC; Jackson SA; Keel S; Chicka M; Brown AL; Kesserwan C; Agarwal A; Luo M; Li Z; Ross JE; Baliakas P; Pineda-Alvarez D; DiNardo CD; Bertuch AA; Mehta N; Vulliamy T; Wang Y; Nichols KE; Malcovati L; Walsh MF; Rawlings LH; McWeeney SK; Soulier J; Raimbault A; Routbort MJ; Zhang L; Ryan G; Speck NA; Plon SE; Wu D; Godley LA
Blood Adv; 2019 Oct; 3(20):2962-2979. PubMed ID: 31648317
[TBL] [Abstract][Full Text] [Related]
8. Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.
Qu S; Li B; Qin T; Xu Z; Pan L; Hu N; Huang G; Peter Gale R; Xiao Z
Br J Haematol; 2021 Mar; 192(6):1006-1010. PubMed ID: 32307695
[TBL] [Abstract][Full Text] [Related]
9. Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes.
Walsh MF; Ritter DI; Kesserwan C; Sonkin D; Chakravarty D; Chao E; Ghosh R; Kemel Y; Wu G; Lee K; Kulkarni S; Hedges D; Mandelker D; Ceyhan-Birsoy O; Luo M; Drazer M; Zhang L; Offit K; Plon SE
Hum Mutat; 2018 Nov; 39(11):1542-1552. PubMed ID: 30311369
[TBL] [Abstract][Full Text] [Related]
10. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants.
Lee K; Krempely K; Roberts ME; Anderson MJ; Carneiro F; Chao E; Dixon K; Figueiredo J; Ghosh R; Huntsman D; Kaurah P; Kesserwan C; Landrith T; Li S; Mensenkamp AR; Oliveira C; Pardo C; Pesaran T; Richardson M; Slavin TP; Spurdle AB; Trapp M; Witkowski L; Yi CS; Zhang L; Plon SE; Schrader KA; Karam R
Hum Mutat; 2018 Nov; 39(11):1553-1568. PubMed ID: 30311375
[TBL] [Abstract][Full Text] [Related]
11. Myeloid neoplasms with germline DDX41 mutation.
Cheah JJC; Hahn CN; Hiwase DK; Scott HS; Brown AL
Int J Hematol; 2017 Aug; 106(2):163-174. PubMed ID: 28547672
[TBL] [Abstract][Full Text] [Related]
12. Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT).
Clark A; Thomas S; Hamblin A; Talley P; Kulasekararaj A; Grinfeld J; Speight B; Snape K; McVeigh TP; Snowden JA
Br J Haematol; 2023 Apr; 201(1):35-44. PubMed ID: 36786081
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular correlates of somatic and germline
Badar T; Nanaa A; Foran JM; Viswanatha D; Al-Kali A; Lasho T; Finke C; Alkhateeb HB; He R; Gangat N; Shah M; Tefferi A; Mangaonkar AA; Litzow MR; Ongie LJ; Chlon T; Ferrer A; Patnaik MM
Haematologica; 2023 Nov; 108(11):3033-3043. PubMed ID: 37199125
[TBL] [Abstract][Full Text] [Related]
14. A practical guide to interpreting germline variants that drive hematopoietic malignancies, bone marrow failure, and chronic cytopenias.
Feurstein S; Hahn CN; Mehta N; Godley LA
Genet Med; 2022 Apr; 24(4):931-954. PubMed ID: 35063349
[TBL] [Abstract][Full Text] [Related]
15. Germline Mutations for Novel Candidate Predisposition Genes in Sporadic Schwannomatosis.
Min BJ; Kang YK; Chung YG; Seo ME; Chang KB; Joo MW
Clin Orthop Relat Res; 2020 Nov; 478(11):2442-2450. PubMed ID: 32281771
[TBL] [Abstract][Full Text] [Related]
16. AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome.
Li P; White T; Xie W; Cui W; Peker D; Zeng G; Wang HY; Vagher J; Brown S; Williams M; Kovacsovics T; Patel JL
Leukemia; 2022 Mar; 36(3):664-674. PubMed ID: 34671111
[TBL] [Abstract][Full Text] [Related]
17. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.
Yang F; Long N; Anekpuritanang T; Bottomly D; Savage JC; Lee T; Solis-Ruiz J; Borate U; Wilmot B; Tognon C; Bock AM; Pollyea DA; Radhakrishnan S; Radhakrishnan S; Patel P; Collins RH; Tantravahi S; Deininger MW; Fan G; Druker B; Shinde U; Tyner JW; Press RD; McWeeney S; Agarwal A
Blood; 2022 Feb; 139(8):1208-1221. PubMed ID: 34482403
[TBL] [Abstract][Full Text] [Related]
18. Gene-specific ACMG/AMP classification criteria for germline APC variants: Recommendations from the ClinGen InSiGHT Hereditary Colorectal Cancer/Polyposis Variant Curation Expert Panel.
Spier I; Yin X; Richardson M; Pineda M; Laner A; Ritter D; Boyle J; Mur P; Hansen TVO; Shi X; Mahmood K; Plazzer JP; Ognedal E; Nordling M; Farrington SM; Yamamoto G; Baert-Desurmont S; Martins A; Borras E; Tops C; Webb E; Beshay V; Genuardi M; Pesaran T; Capellá G; Tavtigian SV; Latchford A; Frayling IM; Plon SE; Greenblatt M; Macrae FA; Aretz S;
Genet Med; 2024 Feb; 26(2):100992. PubMed ID: 37800450
[TBL] [Abstract][Full Text] [Related]
19. [Myeloid neoplasms with germline predisposition].
Yoshida K
Rinsho Ketsueki; 2023; 64(9):949-954. PubMed ID: 37793870
[TBL] [Abstract][Full Text] [Related]
20. Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies.
Chlon TM; Patnaik MM
Am J Hematol; 2023 Nov; 98(11):1673-1676. PubMed ID: 37705260
[No Abstract] [Full Text] [Related]
[Next] [New Search]
